Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 360 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Alternative Treatment Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Effect of a Medicated Topical Therapy , Petrolatum, and No Treatment on Nocturnal Cough

NCT00743990
View directory record Official record
Conditions
Respiratory Tract Diseases
Interventions
Ointment containing camphor, eucalyptus oil, and menthol, Petroleum jelly
Other
Lead sponsor
Penn State University
Other
Eligibility
2 Years to 11 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Jun 11, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

NCT06728410
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation
Interventions
Pemigatinib, Durvalumab
Drug
Lead sponsor
Mehmet Akce
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Early Phase 1 Interventional

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

NCT05281718
View directory record Official record
Conditions
Hemophilia A
Interventions
Factor IX
Drug
Lead sponsor
Tulane University
Other
Eligibility
12 Years to 120 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Metairie, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jun 11, 2026, 5:50 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

NCT03943615
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

NCT00453388
View directory record Official record
Conditions
Acute Myeloid Leukemia in Remission, de Novo Myelodysplastic Syndrome, Fanconi Anemia, Previously Treated Myelodysplastic Syndrome
Interventions
Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Oakland, California • Nashville, Tennessee • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Acupuncture/Moxibustion (Acu/Moxa) for Distal Symmetric Peripheral Neuropathy (DSP) in HIV

NCT00826345
View directory record Official record
Conditions
Peripheral Neuropathy, HIV, AIDS, HIV Infections
Interventions
Acupuncture/Moxibustion
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Phase 1Phase 2 Interventional

Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia

NCT00067405
View directory record Official record
Conditions
Fibromyalgia
Interventions
Intravenous micronutrient therapy
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Evaluate Initial Safety of the HemiBridge™ System in Guided Spinal Growth Treatment of Progressive Idiopathic Scoliosis

NCT01465295
View directory record Official record
Conditions
Scoliosis
Interventions
Mechanical hemiepiphysiodesis using the HemiBridge System
Device
Lead sponsor
SpineForm LLC
Industry
Eligibility
10 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

By Potentially Adding a Century Old Therapeutic Measure to Pain Treatment Regimens Called Osteopathic Manipulative Treatment, Can Help Decrease Muscle and Bone Pain and the Usage of Opioid Pain Medication.

NCT06930196
View directory record Official record
Conditions
Osteopathic Manipulative Treatment
Interventions
Counterstrain, Muscle Energy, High Velocity Low Amplitude, The Ultralign SA201 used for measuring tissue texture changes, IsoTouch
Other · Device
Lead sponsor
Skagit Regional Health
Other
Eligibility
18 Years to 65 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Jun 11, 2026, 5:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effectiveness of Chinese Herbal Therapy for Asthma

NCT00712296
View directory record Official record
Conditions
Asthma
Interventions
ASHMI 4, ASHMI 12, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jun 11, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

Personalized NK Cell Therapy in CBT

NCT02727803
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Myeloid Leukemia With Variant MLL Translocations, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chemotherapy-Related Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Gene Mutation, Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Rituximab, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Biological · Drug · Other + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CoolSculpting of the Flank With Alternate Treatment Parameters

NCT02081196
View directory record Official record
Conditions
Body Fat Disorder
Interventions
The Zeltiq CoolSculpting System
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Sacramento, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Jun 11, 2026, 5:50 AM EDT
Terminated Phase 2 Interventional Results available

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

NCT03459443
View directory record Official record
Conditions
C3 Glomerulonephritis, C3 Glomerulopathy, Immune Complex Membranoproliferative Glomerulonephritis, IC-MPGN, Dense Deposit Disease
Interventions
Danicopan
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Birmingham, Alabama • Stanford, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jun 11, 2026, 5:50 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

NCT04042831
View directory record Official record
Conditions
Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

Alternate Day Buprenorphine Administration, Phase XII - 17

NCT00000235
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 16, 2005 · Synced Jun 11, 2026, 5:50 AM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

NCT03303950
View directory record Official record
Conditions
Anemia, ASXL1 Gene Mutation, EZH2 Gene Mutation, IDH1 Gene Mutation, IDH2 Gene Mutation, Plasma Cell Myeloma, Primary Myelofibrosis, Recurrent Plasma Cell Myeloma, Secondary Myelofibrosis, Thrombocytopenia
Interventions
Busulfan, Cyclophosphamide, Fludarabine, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

NCT03829410
View directory record Official record
Conditions
Metastatic Colorectal Cancer, KRAS Gene Mutation
Interventions
Onvansertib, Bevacizumab, FOLFIRI
Drug · Biological
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Jun 11, 2026, 5:50 AM EDT
Active, not recruiting Phase 2 Interventional

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

NCT03994796
View directory record Official record
Conditions
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Interventions
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
435
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 11, 2026, 5:50 AM EDT
Suspended Phase 1Phase 2 Interventional

A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

NCT07011771
View directory record Official record
Conditions
GBA1 Parkinson Disease
Interventions
gene therapy
Drug
Lead sponsor
Capsida Biotherapeutics, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • New York, New York • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Practicing Alternative Techniques to Heal From Depression: The PATH-D Study

NCT00871299
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Mindfulness Based Cognitive Therapy, Health Enhancement Program and medication management
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Jun 11, 2026, 5:50 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Wound Closure Techniques

NCT00282633
View directory record Official record
Conditions
Wounds, Closure
Interventions
Dermabond
Device
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 30, 2007 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

Alternate-Day Buprenorphine Administration. Phase VII - 8

NCT00000226
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 48 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction

NCT00034021
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder, Sexual Dysfunctions, Psychological
Interventions
Ginkgo Biloba, Sex Therapy (genital focus)
Drug · Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Jun 11, 2026, 5:50 AM EDT
Active, not recruiting Not applicable Interventional

Alternative EndoCrowns Designs for Chairside CAD/CAM

NCT04604314
View directory record Official record
Conditions
Endodontically Treated Teeth
Interventions
CEREC Tessera
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 110 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jun 11, 2026, 5:50 AM EDT